Sign In
Buy FHTX
$3.64
+0.0100 (+0.275%)
At Close: Jun 03, 2026
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
05:15am, Monday, 16'th Sep 2024
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
07:00am, Tuesday, 03'rd Sep 2024
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
10:55am, Monday, 02'nd Sep 2024
The consensus price target hints at an 81.2% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
07:00am, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade
10:55am, Friday, 16'th Aug 2024
The consensus price target hints at a 121.8% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
5 Small Drug Stocks to Buy as Innovation Reaches Peak
09:20am, Friday, 16'th Aug 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates
09:10am, Thursday, 08'th Aug 2024
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago.
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
07:00am, Thursday, 08'th Aug 2024
Topline Phase 1 dose escalation data for FHD-286 in combination with decitabine, in relapsed and/or refractory AML patients, anticipated in the fourth quarter of 2024
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
07:00am, Tuesday, 28'th May 2024
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
06:21pm, Wednesday, 22'nd May 2024
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
07:58am, Monday, 20'th May 2024
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its comm
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Monday, 06'th May 2024
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago.
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
07:00am, Monday, 06'th May 2024
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation ther
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
07:00am, Tuesday, 16'th Apr 2024
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2
